関節リウマチ治療薬の創薬

Rheumatoid Arthritis Drug Discoveries: what the future holds

発行	Espicom Business Intelligence
出版日	2008年03月	商品コード	64755
ページ情報	英文 Pages: 250
価格	US$ 1,740 換算 ¥ 140,400 (税抜) Hard Copy US$ 1,740 換算 ¥ 140,400 (税抜) PDF by E-mail (Single user license) US$ 1,740 換算 ¥ 140,400 (税抜) Web Access (Single user license)

概要
原文目次
関連レポート

原文目次

Abstract

The value of the rheumatoid arthritis (RA) market currently stands at approximately US$11.6 billion and is continuing to grow, driven mainly by the biologic DMARDs. It is dominated by five major pharma companies: Abbott, Amgen, Johnson & Johnson, Schering-Plough and Wyeth, which between them market three of the most successful biologics, the tumour necrosis factor inhibitors Enbrel (etanercept), Remicade (infliximab) and Humira (adalimumab).

Research into new treatments is intense, driven by the need for safer and even more effective medications with more convenient dosing schedules. GlaxoSmithKline, Johnson & Johnson, Roche, Schering-Plough and UCB all have biologics in the late phases of development, while Pfizer is pinning its hopes on its oral kinase inhibitors, which are currently in Phase II development. As these new therapies come on board and the market becomes more competitive, the prospects for RA patients can only improve.

This report provides a complete assessment of the market' s potential

This new management report provides a complete examination of the RA market and its prospects in the medium term. Packed with analysis and forecasts, anyone needing to understand the drivers of this fast growing sector need look no further.

Providing…

Detailed assessment and 5-year forecasts for current leading products by value
A detailed review and assessment of up and coming products
Unique product assessment and scoring

Major approaches

Adenosine receptor antagonist
B-cell targeted therapy
Cathepsin-S inhibitors
Chemokine receptor antagonists
DHODH inhibitors
Glucocorticoids
Interleukin inhibitors
Kinase inhibitors
Lymphotoxin beta and light pathway inhibitor
Non-steroidal anti-inflammatory drugs
RANK ligand inhibitor
T-cell co-stimulation modulator
TNF inhibitors
Traditional disease-modifying anti-rheumatic drugs

INTRODUCTION
WHAT IS RHEUMATOID ARTHRITIS?
- Pathogenesis Of Rheumatoid Arthritis
- Classification Of Rheumatoid Arthritis
- Assessment Of Disease Activity And Response To Treatment
CURRENT TREATMENT OPTIONS
- Diagnosis of Rheumatoid Arthritis
- Pharmacological Therapy
- Treatment Strategies
PATIENT STATISTICS
- Incidence and Prevalence
- The Future
THE RHEUMATOID ARTHRITIS MARKET
- PLAYERS AND PRODUCTS
  - Players And Products In 2007
  - Players And Products In 2015
- DRUG GROWTH DRIVERS AND DAMPENERS
ANALYSIS OF CURRENT LEADING PRODUCTS
- NON-STEROIDAL ANTI-INFLAMMATORY DRUGS
  - Celebrex
  - Arcoxia
  - Mobic
- GLUCOCORTICOIDS
- TRADITIONAL DISEASE-MODIFYING ANTI-RHEUMATIC DRUGS
- BIOLOGICAL AGENTS
  - TNF Inhibitors
    - Remicade
    - Humira
    - Enbrel
  - Interleukin-1 Receptor Inhibitor
    - Kineret
  - B-Cell Targeted Therapy
    - Rituxan/MabThera
  - T-Cell Co-Stimulation Modulator
    - Orencia
RESEARCH AND DEVELOPMENT OF RHEUMATOID ARTHRITIS DRUGS
- LATE-PHASE PROJECTS
  - TNF Inhibitors
    - Cimzia
    - Golimumab
  - Interleukin-6 Receptor Inhibitor
    - Actemra
  - Interleukin-1 Receptor Inhibitor
    - Canakinumab
  - B-Cell Targeted Therapy
    - Ocrelizumab
    - Ofatumumab
  - Non-Steroidal Anti-Inflammatory Drugs
    - Iguratimod
    - PN-400
  - Glucocorticoid
    - Lodotra
- PHASE II PROJECTS
- Oral Therapies
  - Adenosine Receptor Antagonist
    - CF101
  - Cathepsin-S Inhibitor
    - RWJ-445380
  - Chemokine Receptor Antagonists
    - Selzentry
  - DHODH Inhibitor
    - SC12267
  - Interleukin Inhibitors
    - Apilimod
  - Kinase Inhibitors
    - 681323
    - 856553
    - BMS-582949
    - CP-195543
    - CP-690550
    - INCB18424
    - PH-797804
    - SCIO-469
    - Tamatinib
    - VX-702
  - T-Cell Co-Stimulation Modulator
    - RhuDex
  - Other Oral Therapies
    - 274150
    - CH-1504
    - CRx-102
    - K-832
    - PMI-001
    - R7277
- Injectable Therapies
  - B-Cell Targeted Therapy
    - Atacicept
    - LymphoStat-B
    - TRU-015
  - Interleukin Inhibitors
    - AMG 108
  - Lymphotoxin Beta and LIGHT Pathway Inhibitor
    - Baminercept
  - RANK Ligand Inhibitor
    - Denosumab
  - TNF Inhibitor
    - tgAAC94
  - Other Injectable Therapies
    - MM-093
- PHASEI PROJECTS
  - Kinase Inhibitors
    - ARRY-438162
    - ARRY-797
    - MLN0415
  - Anti-TNF
    - ART621
  - Others
    - PRTX-100
    - VAP-1
APPENDIX 1: COMPETITOR RATIO ANALYSIS
APPENDIX 2: COMPANY PROFILES
- 4SC
- Abbott
- Amgen
- Arana Therapeutics
- AstraZeneca
- Biogen Idec
- Bristol-Myers Squibb
- Can-Fite Biopharma
- Chelsea Therapeutics
- Chugai
- CombinatoRx
- Dainippon Sumitomo Pharma
- Eisai
- Eli Lilly
- Genmab
- GlaxoSmithKline
- Human Genome Sciences
- Johnson & Johnson
- Kowa Pharmaceutical
- Medarex
- Medigene
- Merck KGaA
- Merrimack Pharmaceuticals
- Millennium Pharmaceuticals
- Mitsubishi Tanabe Pharma
- Novartis
- Phytomedics
- Pozen
- Pfizer
- Rigel Pharmaceuticals
- Roche
- sanofi-aventis
- Schering-Plough
- Synta Pharmaceuticals
- Takeda
- Targeted Genetics
- Toyama Chemical
- Trubion
- Wyeth
- Vertex Pharmaceuticals
APPENDIX 3: GLOSSARY
APPENDIX 4: SOURCES
APPENDIX 5: PRODUCT INDEX